{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:53:24Z","timestamp":1777578804809,"version":"3.51.4"},"reference-count":48,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) improved progression-free survival (PFS) vs observation (OBS). The host pharmacogenetic background was analyzed to decipher whether single-nucleotide polymorphisms (SNPs) of genes encoding transmembrane transporters, metabolic enzymes, or cell-surface receptors might predict drug efficacy. Genotypes were obtained via real-time polymerase chain reaction of the peripheral blood germ line DNA. Polymorphisms of ABCB1 and VEGF were found in 69% and 79% of 278 patients, respectively, and predicted favorable PFS vs homozygous wild-type (WT) in the LEN arm was 3-year PFS of 85% vs 70% (P\u00a0&amp;lt; .05) and 85% vs 60% (P\u00a0&amp;lt; .01), respectively. Patients carrying both ABCB1 and VEGF WT had the poorest 3-year PFS (46%) and overall survival (76%); in fact, in these patients, LEN did not improve PFS vs OBS (3-year PFS, 44% vs 60%; P\u00a0= .62). Moreover, the CRBN polymorphism (n\u00a0= 28) was associated with lenalidomide dose reduction or discontinuation. Finally, ABCB1, NCF4, and GSTP1 polymorphisms predicted lower hematological toxicity during induction, whereas ABCB1 and CRBN polymorphisms predicted lower risk of grade \u22653 infections. This study demonstrates that specific SNPs represent candidate predictive biomarkers of immunochemotherapy toxicity and LEN efficacy after ASCT in MCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009504","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T17:25:19Z","timestamp":1681493119000},"page":"3764-3774","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"first","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy"},{"name":"2Hematology Division, AOU Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"2Hematology Division, AOU Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"},{"name":"3Hematology Division, AO S.Croce e Carle, Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Arrigoni","sequence":"additional","affiliation":[{"name":"4Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariapia","family":"Pironti","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-5917","authenticated-orcid":false,"given":"Gian Maria","family":"Zaccaria","sequence":"additional","affiliation":[{"name":"5Hematology and Cell Therapy Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Alessandria","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-0337","authenticated-orcid":false,"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"De Luca","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ghislieri","sequence":"additional","affiliation":[{"name":"6Department of Electroniccs and Telecommunications and PolitoBIOMed Lab, Politecnico di Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Tavarozzi","sequence":"additional","affiliation":[{"name":"7Department of Translational Medicine of the Universit\u00e0 degli Studi del Piemonte Orientale, Novara, Italy"},{"name":"8AO SS Antonio e Biagio E Cesare Arrigo, Department of Hematology, Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-9623","authenticated-orcid":false,"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[{"name":"9Hematology, University of Rome Sapienza, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[{"name":"10Hematology Unit, Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"11Department of Oncology and Hematology, Ospedale S. Orsola Malpighi, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[{"name":"1Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy"},{"name":"2Hematology Division, AOU Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[{"name":"2Hematology Division, AOU Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-5115","authenticated-orcid":false,"given":"Monica","family":"Balzarotti","sequence":"additional","affiliation":[{"name":"12Onco-Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Zilioli","sequence":"additional","affiliation":[{"name":"13Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-0531","authenticated-orcid":false,"given":"Filipa","family":"Moita","sequence":"additional","affiliation":[{"name":"14Departamento de Hematologia, Instituto Portugu\u00eas de Oncologia, Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-8325","authenticated-orcid":false,"given":"Elisa","family":"Lucchini","sequence":"additional","affiliation":[{"name":"16UCO Hematology, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Ballerini","sequence":"additional","affiliation":[{"name":"17University of Genoa, S. Martino Hospital, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-6124","authenticated-orcid":false,"given":"Andr\u00e9s J. M.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"18San Raffaele Scientific Institute, Department of Onco-Hematology, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[{"name":"19Hematology Unit, Careggi University Hospital, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"20Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate GF Ingrassia, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-5966","authenticated-orcid":false,"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"21Clinical and Experimental Medicine, Section of Hematology, Pisa University, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Cortelazzo","sequence":"additional","affiliation":[{"name":"22Oncology Unit, Humanitas\/Gavazzeni Cancer Centerter, Dalmine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-6183","authenticated-orcid":false,"given":"Antonello","family":"Di Paolo","sequence":"additional","affiliation":[{"name":"23Section of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"7Department of Translational Medicine of the Universit\u00e0 degli Studi del Piemonte Orientale, Novara, Italy"},{"name":"8AO SS Antonio e Biagio E Cesare Arrigo, Department of Hematology, Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"10044","key":"2023072117502259700_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"2023072117502259700_bib2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023072117502259700_bib3","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(20)30358-6","article-title":"Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial","volume":"8","author":"Ladetto","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"2023072117502259700_bib4","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1002\/ajh.25362","article-title":"Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation","volume":"94","author":"Klener","year":"2019","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"2023072117502259700_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2021-149600","article-title":"Rituximab-lenalidomide (r2) maintenance is superior to rituximab maintenance after first line immunochemotherapy in mantle cell lymphoma: results of the MCL R2 Elderly clinical trial [abstract]. Abstract 2021","volume":"138","author":"Ribrag","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2023072117502259700_bib6","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2023072117502259700_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023072117502259700_bib8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2007-08-106823","article-title":"Prognostic assessment of BCL2-938C&gt;A polymorphism in chronic lymphocytic leukemia","volume":"111","author":"Rossi","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2023072117502259700_bib9","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2010-07-296244","article-title":"The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2023072117502259700_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000267826","article-title":"Vascular endothelial growth factor polymorphisms in mantle cell lymphoma","volume":"123","author":"Galimberti","year":"2010","journal-title":"Acta Haematol"},{"issue":"4","key":"2023072117502259700_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3324\/haematol.2014.108183","article-title":"The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study","volume":"100","author":"Rossi","year":"2015","journal-title":"Hematologica"},{"key":"2023072117502259700_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1475-2867-13-58","article-title":"Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma","volume":"13","author":"Ding","year":"2013","journal-title":"Cancer Cell Int"},{"issue":"15","key":"2023072117502259700_bib13","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/bloodadvances.2020003985","article-title":"Single-nucleotide Fc\u03b3 receptor polymorphisms do not impact obinutuzumab\/rituximab outcome in patients with lymphoma","volume":"5","author":"Strefford","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2023072117502259700_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-017-3481-8","article-title":"Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial","volume":"81","author":"Jakobsen Falk","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"2023072117502259700_bib15","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V120.21.2934.2934","article-title":"Impact of single nucleotide polymorphisms in genes involved in DNA repair and drug metabolism on survival after autologous stem cell transplantation in patients with multiple myeloma","volume":"120","author":"de Larrea","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2023072117502259700_bib16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood.2021014270","article-title":"Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma","volume":"140","author":"Ferrero","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023072117502259700_bib17","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"key":"2023072117502259700_bib18","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.HS9.0000847844.01017.fe","article-title":"P1245: Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: a study from the Fondazione Italiana Iinfomi (fil) phase III mcl0208 trial","volume":"6","author":"Alessandria","year":"2022","journal-title":"Hemasphere"},{"key":"2023072117502259700_bib19","first-page":"47","article-title":"Arlequin ver. 3.0: an integrated software package for population genetics data analysis","volume":"1","author":"Excoffier","year":"2007","journal-title":"Evol Bioinform Online"},{"key":"2023072117502259700_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00049","article-title":"Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi ensures superior data quality and improved assessment of clinical outcomes","volume":"3","author":"Zaccaria","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"5","key":"2023072117502259700_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023072117502259700_bib22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"2023072117502259700_bib23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/leu.2008.398","article-title":"Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2023072117502259700_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3324\/haematol.2014.108183","article-title":"The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study","volume":"100","author":"Rossi","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2023072117502259700_bib25","first-page":"315","article-title":"The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms","volume":"19","author":"Galimberti","year":"2007","journal-title":"J\u00a0Chemother"},{"issue":"1","key":"2023072117502259700_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/10428194.2010.527405","article-title":"Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms","volume":"52","author":"Galimberti","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2023072117502259700_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.15582","article-title":"Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab","volume":"184","author":"Cencini","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2023072117502259700_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12885-021-07891-9","article-title":"Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma","volume":"21","author":"Assis-Mendon\u00e7a","year":"2021","journal-title":"BMC Cancer"},{"issue":"7","key":"2023072117502259700_bib29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/leu.2013.59","article-title":"A\u00a0G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low\/int-1 risk MDS without del(5q)","volume":"27","author":"Sardnal","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2023072117502259700_bib30","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"2023072117502259700_bib31","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2023072117502259700_bib32","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in\u00a0vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2023072117502259700_bib33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mcp.2002.129196","article-title":"Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene","volume":"72","author":"Johne","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2023072117502259700_bib34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00228-003-0567-5","article-title":"Digoxin pharmacokinetics and MDR1 genetic polymorphisms","volume":"58","author":"Verstuyft","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2023072117502259700_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/FTD.0000000000000499","article-title":"Phase II clinical trial of lenalidomide and dexamethasone therapy in japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide","volume":"40","author":"Kobayashi","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"6","key":"2023072117502259700_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12032-019-1280-2","article-title":"Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma","volume":"36","author":"Kobayashi","year":"2019","journal-title":"Med Oncol"},{"issue":"1","key":"2023072117502259700_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2009.11.011","article-title":"The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer","volume":"117","author":"Steffensen","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2023072117502259700_bib38","first-page":"469","article-title":"Association of rs699947 (-2578 C\/A) and rs2010963 (-634 G\/C) single nucleotide polymorphisms of the VEGF Gene, VEGF-A and leptin serum level, and cardiovascular risk in patients with excess body mass: a case-control study","volume":"9","author":"Skrypnik","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"2023072117502259700_bib39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s13277-015-3891-3","article-title":"Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers","volume":"37","author":"Bhaskari","year":"2016","journal-title":"Tumour Biol"},{"issue":"5","key":"2023072117502259700_bib40","doi-asserted-by":"crossref","first-page":"E636","DOI":"10.1002\/ijc.27387","article-title":"Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma","volume":"131","author":"Andersen","year":"2012","journal-title":"Int J Cancer"},{"issue":"5","key":"2023072117502259700_bib41","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3324\/haematol.2017.184325","article-title":"B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial","volume":"103","author":"Bomben","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2023072117502259700_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2021-149600","article-title":"Rituximab-lenalidomide(R2) maintenance is superior to rituximab maintenance after first line immunochemotherapy in mantle cell lymphoma: results of the MCL R2 elderly clinical trial","volume":"138","author":"Ribrag","year":"2021","journal-title":"Blood"},{"key":"2023072117502259700_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00102","article-title":"Precision medicine across the cancer continuum: implementation and implications for cancer disparities","volume":"1","author":"Holt","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"2023072117502259700_bib44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10121","key":"2023072117502259700_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"2023072117502259700_bib46","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023072117502259700_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2023072117502259700_bib48","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3764\/2065433\/blooda_adv-2022-009504-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3764\/2065433\/blooda_adv-2022-009504-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T18:33:20Z","timestamp":1702233200000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3764\/495379\/Candidate-germline-biomarkers-of-lenalidomide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009504","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}